Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

269.95 -3.96 (-1.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
Via Benzinga
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Alnylam Announces New Management Appointments
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
Via Benzinga
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
Via Benzinga
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Alnylam Pharmaceuticals Shares Are Falling
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible 
Via Benzinga
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.  
Via Benzinga
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.